Pancreatic Cancer Precision Medicine Market Size, Share and Trends 2025 to 2034

Pancreatic Cancer Precision Medicine Market Size and Forecast 2025 to 2034

The global pancreatic cancer precision medicine market size accounted for USD 690.11 billion in 2024 and is predicted to increase from USD 823.30 million in 2025 to approximately USD 4,030.16 million by 2034, expanding at a CAGR of 19.30% from 2025 to 2034. The growing adoption of targeted therapies is the key factor driving the growth of the market. Also, the increasing shift towards precision medicine, coupled with the ongoing integration of bioinformatics and next-generation sequencing technologies, can fuel market growth further.

Pancreatic Cancer Precision Medicine Market Key Takeaways

• North America held the largest market share of 43% in 2024.
• Asia Pacific is expected to grow at the fastest CAGR of 7% during the forecast period.
• By therapeutic approach, the targeted therapy segment contributed the highest market share of 57% in 2024.
• By therapeutic approach, the chemotherapy precision combination segment is expected to grow at the fastest CAGR of 21% over the forecast period.
• By diagnostic technology, the genomic testing segment accounted for the biggest market share of 41% in 2024.
• By diagnostic technology, the liquid biopsy segment is projected to grow at a CAGR of 21% during the forecast period.

Role of AI in Improving Pancreatic Disease Diagnosis

Artificial Intelligence plays a transformative role in the pancreatic cancer precision medicine market by improving timely detection, diagnosis, and treatment selection systems by analyzing patient data, medical images, and genomic information to find high-risk groups, tailor treatment plans, and predict survival duration, which can lead to enhanced patient outcomes. Furthermore, AI can help in the progression of computer-assisted diagnostic systems, enhancing overall efficiency and accuracy can also optimise the design and development of newly launched drugs for pancreatic cancer.

• In December 2024, Paris-based Orakl Oncology raised € 11 million to launch AI-powered drug development tools. The funds will be used to accelerate the commercial launch of its AI-powered solutions, O-Predict and O-Validate, and to strengthen strategic collaborations with pharmaceutical partners.

U.S. Pancreatic Cancer Precision Medicine Market Size and Growth 2025 to 2034

The U.S. pancreatic cancer precision medicine market size was exhibited at USD 243.33 million in 2024 and is projected to be worth around USD 1446.32 million by 2034, growing at a CAGR of 19.51% from 2025 to 2034.

North America held the largest pancreatic cancer precision medicine market share in 2024. The dominance of the region can be attributed to the ongoing research and development initiatives in targeted therapies and genetic profiling, along with advanced precision medicine treatments. Moreover, favorable government policies and the surge in the introduction of awareness programs by the government will likely contribute to regional growth soon.

U.S. Market Trends

In North America, the U.S. led the market in 2024, owing to the surge in pancreatic cancer cases in the region, and innovations in liquid biopsies & genomic testing enhance treatment personalization and early disease detection. Also, the raised awareness regarding precision medicine among the majority of players in the region is expanding the country's growth soon.

• In July 2024, Researchers from the American Cancer Society and International Agency for Research on Cancer estimated that 40% of all cancer cases in the United States in people 30 and up were due to "potentially modifiable risk factors," including cigarette smoking, physical inactivity, consumption of processed meat, viruses, excess body weight, alcohol drinking and more.

Asia Pacific is expected to grow at the fastest rate in the pancreatic cancer precision medicine market. The growth of the region can be credited to the surge in pancreatic cancer cases, along with the innovations in healthcare infrastructure and diagnostic settings. Furthermore, the strong presence of well-established critical care centers and hospitals with a huge population suffering from pancreatic cancer is propelling market growth in the region.

China Market Trends

In Asia Pacific, China dominated the pancreatic cancer precision medicine market. The dominance of the country can be driven by an enhancement in healthcare infrastructure and a surge in the number of pharmaceutical market players in the country. Significant investments in cancer research have facilitated the innovation of precision therapies specific to individuals' needs

Market Overview

The pancreatic cancer precision medicine market emphasizes specific treatment plans to individuals' unique properties, rather than utilizing a one-size-fits-all approach. This attitude aims to enhance treatment efficacy and reduce the side effects by tailoring therapies to the key characteristics of each patient's pancreatic cancer. The treatment uses molecular diagnostics and genomic profiling to detect some genetic alterations that cause pancreatic cancer and guide treatment decisions.

Pancreatic Cancer Precision Medicine Market Growth Factors

• The growing investment in research and development is expected to boost the pancreatic cancer precision medicine market growth soon.
• The rapid development of immunotherapies and targeted therapies can propel market growth shortly.
• Regulatory support and government funding will likely contribute to the market expansion during the forecast period.

Market Scope

Market Dynamics

Drivers

Ongoing development of innovative therapies

Lifestyle-related factors and the aging population are the major causes of the increase in pancreatic cancer cases. Innovations in medical technology, including nanotechnology and targeted therapies, provide promising potential. In addition, the surge in government initiatives and increasing awareness about disease treatments propel the investment in research and development of new drugs. Academic institutions and pharmaceutical companies are actively conducting research and development activities.In

• January 2023, Personalized therapy simulation company Cellworks announced the launch of two separate business units that will take an in-silico approach to testing potential new precision oncology drugs in both pre-clinical and clinical stages. The new business units will employ Cellworks' biosimulation and computational bio-simulation model (CBM) to streamline clinical trials.

Restraint

Lack of qualified specialist

The shortage of qualified specialists is the major factor hindering the pancreatic cancer precision medicine market growth. The high treatment costs and limited healthcare infrastructure in developing nations are also negatively affecting market expansion. However, a lack of public awareness and stringent regulatory guidelines can restrict market expansion. The disease also remains asymptomatic in the first stages, which makes it challenging to detect and delay treatment further.

Opportunity

Strong presence of pipeline products

Shifting the focus of major players in R&D activities to launch new drugs and a surge in funding for cancer treatment and research can lead to the development of innovative drugs and treatments in the pancreatic cancer precision medicine market. Furthermore, many pharmaceutical companies are engaged in clinical trials to explore the effect and potential of the molecule for disease treatment. Also, researchers and scientists from various research institutes are emphasizing more towards the development of individualized medicines for pancreatic cancer treatment.

According to the October 2024, Gov.UK, press release, NHS cancer patients are benefitting from partnerships with pharmaceutical companies and universities to spot cancer sooner through trials for new technologies, such as AI. Innovations have the potential to transform treatment for NHS patients and launch a wave of globally significant new Medtech products.

Therapeutic Approach Insights

The targeted therapy segment dominated the pancreatic cancer precision medicine market in 2024. The dominance of the segment can be attributed to the innovation in genomic profiling and individualized treatment. These therapy options provide benefits such as fewer side effects, less harm to healthy cells, and enhanced effectiveness compared to conventional chemotherapy. Additionally, targeted therapies can be specific to genetic characteristics or mutations found in a patient's tumor, enabling more effective and personalized treatment.

• In August 2024, Servier's VORANIGO® (vorasidenib) tablets received FDA approval as the first targeted therapy for Grade 2 IDH-mutant Glioma.VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.

The chemotherapy precision combination segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be credited to the increasing shift towards integrating chemotherapy with precision medicine. Chemotherapy precision can lead to better rates of tumor response and longer survival times for some patients, especially those with specific genetic mutations. Also, regulatory support can optimize the development and approval of these advanced therapies, impacting positive segment growth soon.

Diagnostic Technology Insights

The genomic testing segment held the largest pancreatic cancer precision medicine market share in 2024. The dominance of the segment can be linked to the raised funding and regulatory support for genomic testing, coupled with advanced genomic testing technologies. Moreover, genomic testing can reveal inherited mutations, particularly guiding treatment choices and informing other members of the family regarding the risk of developing cancer. Genomic studies facilitate a deeper understanding of pancreatic cancer.

The liquid biopsy segment is projected to grow at the fastest rate during the forecast period. The growth of the segment can be driven by the benefits offered by liquid biopsies, such as early detection and timely monitoring. Unlike conventional biopsies, liquid biopsies are less invasive and enable more rapid sampling, offering a dynamic view of tumor properties and treatment response. Furthermore, liquid biopsies can offer information regarding potential mutations, drug resistance, and other factors, helping in planning customized treatment strategies.

• In September 2024, Strand Life Sciences, a subsidiary of Reliance Industries Limited, announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test. According to the company's statement, this test detects circulating tumor DNA in blood samples of cancer patients to provide a comprehensive analysis of 74 clinically relevant genes, providing invaluable insights for cancer treatment.

Pancreatic Cancer Precision Medicine Market Companies

• AstraZeneca
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd
• PharmaCyte Biotech, Inc.
• Genentech, Inc.

Latest Announcement by Market Leaders

• In March 2025, AstraZeneca announced a USD 2.5 billion investment in a research and development hub in Beijing, underscoring its commitment to China, its second-largest market. This initiative includes two licensing deals with Chinese firms and aims to leverage Beijing's advanced life sciences and AI capabilities. Chief executive Pascal Soriot highlights the extensive collaboration opportunities and access to talent in China.
• In January 2025, Pfizer Inc. announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

Recent Developments

• In August 2024, a new study explored the use of a repurposed chemotherapy drug in combination with nanotechnology to improve drug delivery and effectiveness against pancreatic cancer. This approach aims to make the treatment more targeted and reduce side effects, potentially opening up new possibilities for more effective therapies.
• In March 2024, Bayer AG and Thermo Fisher Scientific partnered to develop NGS-based companion diagnostics, enhancing patient access to precision cancer therapies through decentralized genomic testing and rapid results.
• In March 2024, Bayer AG and Aignostics GmbH collaborated on AI-powered precision oncology, developing novel target identification platforms and algorithms to accelerate clinical development and improve patient selection in trials.
• In July 2023, a combination immunotherapy approach using the pancreatic cancer vaccine GVAX, along with immune checkpoint therapy and an antibody, showed a promising immune response in operable pancreatic cancers. This three-pronged treatment could pave the way for more effective immunotherapy protocols soon.

Segments Covered in the Report

By Therapeutic Approach

• Targeted Therapy
• PARP Inhibitors
• Monoclonal Antibodies
• Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
• Immunotherapy
• Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
• Cancer Vaccines - GVAX, Algenpantucel-L
• Adoptive T-Cell Therapies - CAR-T therapies
• Chemotherapy-Precision Combinations
• Other Therapeutic Approaches

By Diagnostic Technology

• Genomic Testing
• Molecular Diagnostics
• Liquid Biopsy
• Biomarker-based Companion Diagnostics
• Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa